Equity Research Medical Devices

Should You Buy Medtronic plc. Stock in 2026?

By CirclFi Research Team · · 12/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Medtronic plc. (MDT) is rated as a strong fundamental performer with a QOC score of 8.1/10. Trading at $83.20, our valuation engine evaluates whether the market price reflects the company's underlying earnings power.

The short answer: 2 of 12 CirclFi valuation models project upside for Medtronic plc. (MDT) at $83.20 — the model consensus leans bearish, with a Quality Score of 8.1/10 and Value-Trap risk of 12/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 10 of 12 models suggest overvaluation — majority bearish
  • Quality Score: 8.1/10 — Excellent — top-tier fundamentals
  • Value Trap Risk: 12/100 — Minimal — healthy fundamentals
  • Fair Value Range: $21.47 – $86.70 (304% spread)

Bullish Models

2 / 12

Bearish Models

10 / 12

Quality Score

8.1 /10

Excellent — top-tier fundamentals

Value Trap Risk

12 /100
Minimal

Minimal — healthy fundamentals

Model Consensus

12 /13
Active Models

Avg. confidence: 59%

Investment Thesis

The Bull Case

Target: $86.70 (+4.2% upside)

  • According to the CirclFi Quality of Company (QOC) framework, Medtronic plc.'s score of 8.1/10 reflects durable competitive advantages that should sustain earnings power through market cycles.
  • Industry tailwind: orphan drug designation could provide meaningful support for Medtronic plc.'s revenue and margin trajectory in the Medical Devices space.
  • The company's $106.5B market capitalization provides liquidity, stability, and the resource base to invest through downturns — structural advantages over smaller peers.

The Bear Case

Target: $21.47 (-74.2%)

  • According to the CirclFi Deep Alpha Valuation Engine, the Earnings Power Value (EPV) model sees the stock as overvalued with a fair value of $21.47 (-74.2%), suggesting that the market price embeds overly optimistic growth assumptions.
  • According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +78.4% spread between the most bullish and bearish models, signaling elevated analytical uncertainty.
  • Industry headwind: patent expiration revenue loss represents a meaningful risk for Medtronic plc. and its Medical Devices peers.

Peer Benchmarking

DXCM DexCom, Inc.
10.0
IRMD iRadimed Corporation
10.0
PODD Insulet Corporation
10.0
ABT Abbott Laboratories
10.0
INMD InMode Ltd.
9.9

See full Medical Devices rankings →

Valuation Divergence

Spread

304%

Fair Value Range

$21.47 – $86.70

A 304% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

FTNN

$86.70 (+4.2%)

Most Bearish

EPV

$21.47 (-74.2%)

Key Risk Factors

Model Disagreement

304% spread signals high variance in projections.

Bearish Consensus

10/12 models suggest overvaluation.

Macro/Sector Risk

Medical Devices headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View MDT Data Page →

The Bottom Line

Our valuation engine sends a clear cautionary signal on Medtronic plc. at $83.20. 10/12 models flag overvaluation, composite fair value sits at $49.16 (-40.9%), and the risk-reward profile appears unfavorable. Quality at 8.1/10 is the one bright spot, but premium quality at the wrong price can still destroy returns. This is a stock where patience — or avoidance — may be the optimal strategy.

These are quantitative model outputs, not investment recommendations. Medtronic plc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

Frequently Asked Questions

Should I buy MDT stock right now?

Based on CirclFi's multi-model analysis, 2 of 12 models see upside for MDT at $83.20. The models are divided, which means the investment case depends heavily on your assumptions about Medtronic plc.'s future. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Medtronic plc.?

Key risks include: wide model disagreement (304% spread), signaling high uncertainty; general market and sector-specific risks affecting Medical Devices companies. Always diversify and consult a financial advisor.

How does MDT compare to its competitors?

Among Medical Devices peers, MDT holds a Quality Score of 8.1/10. Comparable companies include DXCM (QOC 10.0), IRMD (QOC 10.0), PODD (QOC 10.0). The relative ranking helps investors identify whether MDT offers better fundamental quality than alternatives in the same sector.

Is MDT a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. MDT's Quality Score of 8.1/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.

What price should I buy MDT at?

CirclFi does not provide target buy prices or price alerts. However, our 12 active models produce fair value estimates ranging from $21.47 to $86.70. At $83.20, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for MDT.

View MDT Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →